In today’s session Boston Scientific Corporation (BSX) recorded an unusually high (373) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious BSX decrease. With 373 contracts traded and 18954 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: BSX170120P00022000 closed last at: $0.79 or 1.3% up. About 2.67 million shares traded hands. Boston Scientific Corporation (NYSE:BSX) has risen 26.52% since March 14, 2016 and is uptrending. It has outperformed by 20.90% the S&P500.
Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on October, 26. They expect $0.27 EPS, up 12.50% or $0.03 from last year’s $0.24 per share. BSX’s profit will be $364.14M for 21.14 P/E if the $0.27 EPS becomes a reality. After $0.27 actual EPS reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Boston Scientific Corporation (NYSE:BSX) Ratings Coverage
Out of 22 analysts covering Boston Scientific Corporation (NYSE:BSX), 17 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 77% are positive. Boston Scientific Corporation has been the topic of 29 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, April 28 report. The rating was initiated by Nomura on Thursday, March 17 with “Buy”. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Sunday, September 6 by BTIG Research. The stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given on Thursday, November 12 by Citigroup. On Thursday, April 28 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Neutral” rating by Wedbush on Friday, July 29. On Thursday, August 13 the stock rating was downgraded by TheStreet to “Hold”. The rating was upgraded by Goldman Sachs to “Neutral” on Thursday, August 27. The firm has “Buy” rating by Benchmark given on Thursday, July 23. The stock has “Buy” rating given by SunTrust on Thursday, February 25.
According to Zacks Investment Research, “Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The company’s products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.”
Insitutional Activity: The institutional sentiment increased to 1.16 in Q2 2016. Its up 0.23, from 0.93 in 2016Q1. The ratio is positive, as 25 funds sold all Boston Scientific Corporation shares owned while 168 reduced positions. 63 funds bought stakes while 160 increased positions. They now own 1.23 billion shares or 2.15% less from 1.26 billion shares in 2016Q1.
Capstone Invest Limited Liability Corporation last reported 78,862 shares in the company. Stevens Cap L P last reported 212,735 shares in the company. State Of Wisconsin Invest Board holds 847,350 shares or 0.08% of its portfolio. Highland Cap Mngmt Limited Partnership last reported 0.92% of its portfolio in the stock. Deroy & Devereaux Private Invest Counsel Incorporated last reported 1.66% of its portfolio in the stock. Centurylink Inv accumulated 0.61% or 73,731 shares. Point72 Asia (Hong Kong) Limited last reported 116,341 shares in the company. Mirae Asset Invests Limited has 0.08% invested in the company for 135,285 shares. Euclid Advsr holds 0.1% or 97,062 shares in its portfolio. Nj State Employees Deferred Compensation Plan last reported 0.2% of its portfolio in the stock. The Tennessee-based First Mercantile has invested 0.17% in Boston Scientific Corporation (NYSE:BSX). Shell Asset Mgmt holds 0.1% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 175,658 shares. Commonwealth Of Pennsylvania School Empls Retrmt Systems holds 0.05% or 108,641 shares in its portfolio. Perkins Capital accumulated 50,650 shares or 1.36% of the stock. Orbimed Advsr holds 23.13 million shares or 5.64% of its portfolio.
Insider Transactions: Since April 27, 2016, the stock had 0 insider buys, and 16 insider sales for $15.01 million net activity. 24,000 shares were sold by Pratt Timothy A., worth $526,438 on Monday, May 2. Sorenson John Bradley also sold $62,020 worth of Boston Scientific Corporation (NYSE:BSX) on Wednesday, May 11. Shares for $1.74 million were sold by Fitzgerald Joseph Michael. Another trade for 78,122 shares valued at $1.88M was sold by Ballinger Kevin J.. Phalen Michael P. had sold 35,000 shares worth $841,050. 80,000 Boston Scientific Corporation (NYSE:BSX) shares with value of $1.77M were sold by Dawkins Keith D. Mirviss Jeffrey B. also sold $541,038 worth of Boston Scientific Corporation (NYSE:BSX) shares.
Boston Scientific Corporation is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The company has a market cap of $30.79 billion. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions , Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It currently has negative earnings. It operates in three divisions: Cardiovascular, Rhythm Management and MedSurg.
BSX Company Profile
Boston Scientific Corporation, incorporated on June 22, 1979, is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. The Firm operates through three divisions: Cardiovascular, Rhythm Management and MedSurg. The Company’s Cardiovascular segment consists of Interventional Cardiology and PI businesses. The Company’s Rhythm Management segment consists of CRM and EP businesses. The Company’s MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses.
More important recent Boston Scientific Corporation (NYSE:BSX) news were published by: Prnewswire.com which released: “Boston Scientific to Webcast Conference Call Discussing Third Quarter 2016 …” on October 03, 2016, also Prnewswire.com published article titled: “Professor Ian Meredith To Join Boston Scientific As Executive Vice President …”, Prnewswire.com published: “Boston Scientific Receives CE Mark For LOTUS Edgeâ„¢ Valve System” on September 19, 2016. More interesting news about Boston Scientific Corporation (NYSE:BSX) was released by: Prnewswire.com and their article: “Abbott Vascular, Boston Scientific Corporation and Cordis in the Growth of the …” with publication date: September 30, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.